Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed.
Cascading damage toProceedings of the National Academy of Sciences of the United States of America · 2026
Article
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Wanjun Qi *Division of Infectious Diseases, Boston Children's Hospital/Harvard Medical School, Boston, MA 02115.ORCID 0000-0003-4593-5734
Udita Roy *Division of Infectious Diseases, Boston Children's Hospital/Harvard Medical School, Boston, MA 02115.ORCID 0000-0001-7363-6083
Chunhui CaiResearch Informatics, Department of Information Technology, Boston Children's Hospital, Boston, MA 02115.ORCID 0000-0002-1742-4999
Maikel Acosta-ZaldívarDivision of Infectious Diseases, Boston Children's Hospital/Harvard Medical School, Boston, MA 02115.ORCID 0000-0002-9562-6887
Jossalyn MascioDivision of Infectious Diseases, Boston Children's Hospital/Harvard Medical School, Boston, MA 02115.ORCID 0009-0001-2314-4328
John M AsaraDivision of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 02115.ORCID 0000-0001-7450-2589
José F FierroLaboratory of Oral Microbiology, University Clinic of Dentistry, University of Oviedo, Oviedo 33006, Asturias, Spain.ORCID 0000-0003-2752-0690
María T AndrésLaboratory of Oral Microbiology, University Clinic of Dentistry, University of Oviedo, Oviedo 33006, Asturias, Spain.ORCID 0000-0002-7827-981X
Liang SunResearch Informatics, Department of Information Technology, Boston Children's Hospital, Boston, MA 02115.ORCID 0000-0002-0321-9222
Julia R KöhlerDivision of Infectious Diseases, Boston Children's Hospital/Harvard Medical School, Boston, MA 02115.ORCID 0000-0003-3015-9015
Funding
Candida albicans Target of Rapamycin in oxidative stress responsesR21AI178693 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI JULIA R KOEHLER · 2025 to 2026
$481k
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R21AI178693NIAID NIH HHS R21 AI178693
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.